Specification
| Target | CD20xCD3 |
| Clone | Mosunetuzumab |
| Isotype | Human IgG1(N297G/T366S/L368A/Y407V)-Human IgG1(N297G/T366W)-Kappa |
| Expression System | CHO |
| Purification | Protein A |
| Recommended Isotope Control | |
| Recommended Dilution Buffer | PBS, pH 7.51 |
| Formulation | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Storage | This antibody can be storaged at 2°C to 8 °C for 2 weeks under sterile conditions;-20°C for 3 months under sterile conditions;-70°C for 36 months under sterile conditions.Avoid repeated freeze-thaw. |
| Disclaim | For Research Use Only |
Background
| Background | Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody.4 It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells.1 The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as rituximab, in combination with chemotherapy. However, patients with certain types of B-cell lymphoma, such as follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) or aggressive B-cell lymphoma, have a high probability of relapse or recurrence after treatment.1,3 Mosunetuzumab has the potential to circumvent resistance to rituximab in patients with follicular lymphoma,1,4 and unlike CAR-T therapies such as axicabtagene ciloleucel and tisagenlecleucel, it is an “off-the-shelf” alternative, readily available to patients.5 In June 2022, the European Medicines Agency approved mosunetuzumab for the treatment of adult patients with relapsed or refractory (R/R) FL who have received at least two prior systemic therapies. |
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |